210 related articles for article (PubMed ID: 9400440)
1. New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma.
Patel A; Fuchs GJ
J Urol; 1998 Jan; 159(1):71-5. PubMed ID: 9400440
[TBL] [Abstract][Full Text] [Related]
2. Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract.
Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Nishimura K; Takaha N; Takahara S; Okuyama A
Eur Urol; 2000 Dec; 38(6):701-4;discussion 705. PubMed ID: 11111187
[TBL] [Abstract][Full Text] [Related]
3. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.
Thalmann GN; Markwalder R; Walter B; Studer UE
J Urol; 2002 Oct; 168(4 Pt 1):1381-5. PubMed ID: 12352398
[TBL] [Abstract][Full Text] [Related]
4. Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys.
Chen GL; Bagley DH
J Urol; 2000 Oct; 164(4):1173-6. PubMed ID: 10992360
[TBL] [Abstract][Full Text] [Related]
5. Retrograde endoscopic laser therapy and ureteroscopic surveillance for transitional cell carcinoma of the upper urinary tract.
Mugiya S; Ozono S; Nagata M; Otsuka A; Takayama T; Nagae H
Int J Urol; 2006 Jan; 13(1):1-6. PubMed ID: 16448423
[TBL] [Abstract][Full Text] [Related]
6. Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma.
Keeley FX; Bibbo M; Bagley DH
J Urol; 1997 May; 157(5):1560-5. PubMed ID: 9112476
[TBL] [Abstract][Full Text] [Related]
7. Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma.
Boorjian S; Ng C; Munver R; Palese MA; Vaughan ED; Sosa RE; Del Pizzo JJ; Scherr DS
Urology; 2005 Aug; 66(2):283-7. PubMed ID: 16098357
[TBL] [Abstract][Full Text] [Related]
8. Management of primary upper urinary tract carcinoma in situ diagnosed by ureteroscopic biopsy: Is bacillus Calmette-Guerin an alternative to nephroureterectomy?
Territo A; Fontanet S; Meneghetti I; Gallioli A; Sanguedolce F; Rodriguez-Faba Ó; Gaya JM; Palou J; Huguet J; Breda A
Actas Urol Esp (Engl Ed); 2023 May; 47(4):221-228. PubMed ID: 36379260
[TBL] [Abstract][Full Text] [Related]
9. Bilateral renal masses after local Bacillus Calmette-Guerin therapy for postcystectomy ureteral cancer.
Squires FB; Coakley FV; Berg WJ; Panicek DM
Abdom Imaging; 1999; 24(2):200-1. PubMed ID: 10024413
[TBL] [Abstract][Full Text] [Related]
10. [Intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract].
Okubo K; Ishitoya S; Maeda H; Suzuki Y; Arai Y
Nihon Hinyokika Gakkai Zasshi; 1997 Mar; 88(3):386-90. PubMed ID: 9125861
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma.
Keeley FX; Bagley DH
J Urol; 1997 Dec; 158(6):2074-7. PubMed ID: 9366315
[TBL] [Abstract][Full Text] [Related]
12. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience.
Cutress ML; Stewart GD; Wells-Cole S; Phipps S; Thomas BG; Tolley DA
BJU Int; 2012 Dec; 110(11):1608-17. PubMed ID: 22564677
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous management of renal pelvic urothelial tumors: long-term followup.
Goel MC; Mahendra V; Roberts JG
J Urol; 2003 Mar; 169(3):925-9; discussion 929-30. PubMed ID: 12576814
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of upper urinary tract transitional cell carcinoma: the role of ureteroscopy, retrograde pyelography, cytology and urinalysis.
Chen GL; El-Gabry EA; Bagley DH
J Urol; 2000 Dec; 164(6):1901-4. PubMed ID: 11061876
[TBL] [Abstract][Full Text] [Related]
15. Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG.
Miller EB; Eure GR; Schellhammer PF
Urology; 1993 Jul; 42(1):26-30. PubMed ID: 8328123
[TBL] [Abstract][Full Text] [Related]
16. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
[TBL] [Abstract][Full Text] [Related]
17. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review.
Cutress ML; Stewart GD; Zakikhani P; Phipps S; Thomas BG; Tolley DA
BJU Int; 2012 Sep; 110(5):614-28. PubMed ID: 22471401
[TBL] [Abstract][Full Text] [Related]
18. Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients.
Grasso M; Fishman AI; Cohen J; Alexander B
BJU Int; 2012 Dec; 110(11):1618-26. PubMed ID: 22458598
[TBL] [Abstract][Full Text] [Related]
19. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.
Metcalfe M; Wagenheim G; Xiao L; Papadopoulos J; Navai N; Davis JW; Karam JA; Kamat AM; Wood CG; Dinney CP; Matin SF
J Endourol; 2017 Sep; 31(9):946-953. PubMed ID: 28731777
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of intrarenal Bacillus Calmette-Guérin/interferon-α2B for biopsy-proven upper-tract carcinoma in situ.
Shapiro EY; Lipsky MJ; Cha DY; McKiernan JM; Benson MC; Gupta M
J Endourol; 2012 Dec; 26(12):1645-50. PubMed ID: 22834939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
